RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Zelira Therapeutics Stock

Zelira Therapeutics Market capitalization 2025

Zelira Therapeutics Market capitalization

7.38 M AUD

Ticker

ZLD.AX

ISIN

AU000000ZLD1

WKN

A2AS5H

In 2025, Zelira Therapeutics's market cap stood at 7.38 M AUD, a -26.66% increase from the 10.06 M AUD market cap in the previous year.

The Zelira Therapeutics Market capitalization history

YEARMarket Capitalization (undefined AUD)
20247.84
202311.57
20228.18
20210.36
20200.29
20190.26
20180.39
20170.21
20160.02
20151.69
20141
20131.25
20121.76
20114.35
20104.77
20099.54
20085.26
20074.27
20064.59
20051.62

Zelira Therapeutics Aktienanalyse

What does Zelira Therapeutics do?

Zelira Therapeutics was founded in 2016 with its headquarters in Perth, Australia. The company focuses on the development, production, and marketing of medical cannabis to meet the needs of patients worldwide. The company's business model is based on producing medical cannabis specifically tailored to patients' needs. It works closely with doctors and patients to ensure its products are effective and meet patients' needs. Zelira Therapeutics operates in three main areas. The first is the development of products for treating pain and inflammation in chronic conditions such as multiple sclerosis, cancer, and epilepsy. The second area includes the development of products for treating sleep disorders. The third area is the development of products for treating mental disorders such as anxiety and depression. The company has developed a wide range of products, including oils, pills, sprays, and topical creams. An example of a product is the ZTL-101 oil, which was developed for treating pain and inflammation in patients with osteoarthritis. The oil contains a combination of CBD and THC. The company has also partnered with the University of Mississippi to research the use of medical cannabis for treating post-traumatic stress disorder (PTSD). The research is funded by the US government and aims to legitimize the use of medical cannabis for treating PTSD. Zelira Therapeutics has also formed partnerships with other companies and organizations to advance its research and development. In 2020, the company entered into an agreement with Emerald Health Therapeutics, a Canadian company specializing in the production of medical cannabis. The two companies will collaborate on developing products for treating sleep disorders. The company has also partnered with iCAN Israel-Cannabis, an Israel-based company specializing in the research and development of medical cannabis. The two companies are working together to develop new products and promote the use of medical cannabis in various countries. In addition to its partnerships, Zelira Therapeutics has established a strong presence in various international markets. It is currently operating in the US, Australia, New Zealand, and Germany, and is working to expand into other countries. Overall, Zelira Therapeutics is a company specializing in the development of medical cannabis for treating various conditions. It has a wide range of products and works closely with doctors and patients to ensure their effectiveness and meet patients' needs. With strong partnerships and a presence in various international markets, the company has a promising future. Zelira Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Zelira Therapeutics's Market Capitalization

Zelira Therapeutics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Zelira Therapeutics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Zelira Therapeutics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Zelira Therapeutics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Zelira Therapeutics stock

What is the current Zelira Therapeutics market capitalization?

The current market capitalization of Zelira Therapeutics is 7.38 M AUD.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Zelira Therapeutics.

How has the market capitalization of Zelira Therapeutics developed in recent years?

The market capitalization of Zelira Therapeutics has increased/decreased by -26.66% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Zelira Therapeutics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Zelira Therapeutics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Zelira Therapeutics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Zelira Therapeutics pay?

Over the past 12 months, Zelira Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zelira Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Zelira Therapeutics?

The current dividend yield of Zelira Therapeutics is .

When does Zelira Therapeutics pay dividends?

Zelira Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zelira Therapeutics?

Zelira Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Zelira Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zelira Therapeutics located?

Zelira Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zelira Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zelira Therapeutics from 1/8/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 1/8/2025.

When did Zelira Therapeutics pay the last dividend?

The last dividend was paid out on 1/8/2025.

What was the dividend of Zelira Therapeutics in the year 2024?

In the year 2024, Zelira Therapeutics distributed 0 AUD as dividends.

In which currency does Zelira Therapeutics pay out the dividend?

The dividends of Zelira Therapeutics are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Zelira Therapeutics

Our stock analysis for Zelira Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zelira Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.